此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

抑郁症住院患者的急性心理睡眠稳定

2026年11月3日 更新者:Sandra Tamm、Karolinska Institutet

Disturbed sleep occurs in almost all patients in psychiatric inpatient care, and although it is well known that comorbid sleep disorders in depression often persist after treatment of depression and also increase the risk of new depressive episodes, the availability of effective, evidence-based treatments for sleep disorders in hospitalised patients is very limited.

The overall goal of the current project is to translate, adapt and evaluate an acute psychological sleep treatment based on cognitive behavioural therapy for insomnia (CBT-I) for patients hospitalized with depression and comorbid sleep problems in the specialized psychiatric inpatient care in the Stockholm Region. The main hypothesis for the study is that acute psychological sleep stabilization (APS) reduces self-reported sleep complains compared to care as usual reinforced with sleep hygiene advice, and secondary hypotheses are that APS also leads to reduced depressive symptoms and earlier discharge.

The project includes a pilot study, which will be followed by a randomized, controlled trial of APS compared to care as usual with structured sleep hygiene (minimal active control) and treatment effect is evaluated every three days during the hospital stay and 1,2,4 and 12 weeks after randomization. APS will be performed by existing staff in the department with the support of a psychologist.

研究概览

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Stockholm、瑞典
        • Psykiatri Sydväst, Karolinska Hospital Huddinge

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Admitted to the psychiatric inpatient care (Psykiatri Sydväst)
  • Depressive symptoms / confirmed depressive episode (uni- or bipolar)
  • Reports or is observed to have sleep problems in the form of insomnia, hypersomnia or delayed circadian phase
  • Knowledge of Swedish or English that is deemed sufficient to undergo the treatment
  • Consent to be included in the study and is judged to have understood what the study entails (care according to the Compulsory Psychiatric Care Act is not in itself an exclusion criterion)

Exclusion Criteria:

  • Dementia
  • Intellectual disability
  • Severe somatic comorbidity with life expectancy <6 months
  • Ongoing mania / mixed-state
  • Complex problems that make APS impossible or inappropriate
  • Expected discharge within 3 days

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Acute psychological sleep stabilization

The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants) together with a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed).

See above (arm description)

有源比较器:Sleep hygiene education

The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music).

See above (arm description)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Insomnia Severity Index
大体时间:2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)

A self-report measure of insomnia symptoms. 7-item, self-rated questionnaire measuring insomnia severity. Total score 0-28, higher score indicates more severe sleep problems.

2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)

次要结果测量

结果测量
措施说明
大体时间
Patient Health Questionnaire (PHQ-9)
大体时间:Day 4, 7, 10 14 and week 4 and 12 post randomisation

Self-reported depressive symptoms. PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Total score 0-27, higher score indicates more severe depressive symptoms.

Day 4, 7, 10 14 and week 4 and 12 post randomisation
Generalised Anxiety Disorder 7-item scale (GAD-7)
大体时间:Day 4, 7, 10 14 and week 4 and 12 post randomisation

Self-reported anxiety symptoms. A seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder/symptoms. Total score 0-27. Higher scores indicative of more severe problem.

Day 4, 7, 10 14 and week 4 and 12 post randomisation
European Quality of Life 5 Dimensions scale (EQ-5D)
大体时间:Week 2, 4 and 12 post randomisation

Self-reported quality of life. An instrument which evaluates the generic quality of life developed in Europe and widely used. The scale comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

Week 2, 4 and 12 post randomisation

其他结果措施

结果测量
措施说明
大体时间
Sleep Diary
大体时间:0-14 days post randomisation

Participants will report their bedtime, risetime, amount of sleep daily using a simplified version of a sleep diary. We will look at total sleep time, sleep efficiency, and timing of sleep.

0-14 days post randomisation
Actigraphy
大体时间:0-14 days post randomisation

An actigraph is placed on the participant's arm for 2 weeks. It measures participants' arm-movements. An algorithm can be used to estimate sleep from movement data.Data from actigraphs will be reported and analysed

0-14 days post randomisation
Side effects of treatment
大体时间:Day 7 and 14 post randomisation

Patients will be asked to report any side-effects of the treatment with an open question

Day 7 and 14 post randomisation
Treatment Credibility Scale
大体时间:Day 4 post randomisation

A five-item version of Credibility/Expectancy Questionnaire, total score ranging from 0-50. Higher scores indicative of higher credibility.

Day 4 post randomisation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Sandra Tamm、Karolinska Institutet
  • 首席研究员:Susanna Jernelöv、Karolinska Institutet

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月7日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2027年3月1日

研究注册日期

首次提交

2023年11月17日

首先提交符合 QC 标准的

2023年11月17日

首次发布 (实际的)

2023年11月24日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual data will not be shared

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅